Genelux (GNLX) Cash from Financing Activities (2022 - 2026)
Genelux's (GNLX) quarterly Cash from Financing Activities came in at $18.5 million in Q1 2026, up 93.77% year-on-year from $9.6 million in Q1 2025, and up 6616.67% quarter-over-quarter from $276000.0 in Q4 2025.
Genelux (GNLX) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Genelux's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $18.5 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 93.77% year-over-year to $18.5 million in Q1 2026; TTM through Mar 2026 was $18.9 million, a 49.54% decrease from a year earlier, with the FY2025 full-year figure at $9.9 million, down 65.29% from the prior year.
- Cash from Financing Activities climbed to $18.5 million in Q1 2026 per GNLX's latest filing, from $276000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $27.7 million in Q2 2024 and bottomed at -$130000.0 in Q1 2022.
- The 5-year median for Cash from Financing Activities is $688000.0 (2024), against an average of $7.8 million.
- Across the five-year window, Cash from Financing Activities jumped 11361.54% in 2023 and plunged 99.81% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $545000.0 in 2022, then retreated by 26.42% to $401000.0 in 2023, then tumbled by 77.31% to $91000.0 in 2024, then surged by 203.3% to $276000.0 in 2025, then soared by 6616.67% to $18.5 million in 2026.
- Per Business Quant, the three latest GNLX Cash from Financing Activities figures stand at $18.5 million (Q1 2026), $276000.0 (Q4 2025), and $52000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Genelux | 128.48 Mn | 128.48 Mn | - | 18.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.54 Mn |
| Mar 31, 2026 | 18.54 Mn |
| Dec 31, 2025 | 276,000.00 |
| Dec 31, 2025 | 276,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Mar 31, 2025 | 9.57 Mn |
| Mar 31, 2025 | 9.57 Mn |
| Dec 31, 2024 | 91,000.00 |
| Dec 31, 2024 | 91,000.00 |
| Jun 30, 2024 | 27.73 Mn |
| Jun 30, 2024 | 27.73 Mn |
| Mar 31, 2024 | 688,000.00 |
| Mar 31, 2024 | 688,000.00 |
| Dec 31, 2023 | 401,000.00 |
| Dec 31, 2023 | 401,000.00 |
| Sep 30, 2023 | 6.36 Mn |
| Sep 30, 2023 | 6.36 Mn |
| Jun 30, 2023 | 22.62 Mn |
| Jun 30, 2023 | 22.62 Mn |